Therefore, we believe that regardless of whether a patient is diagnosed with GBM-PNC, if pathological examination of the tumor tissue reveals high Ki-67 expression and absence or reduced expression of GFAP, additional genetic testing should be promptly performed, and the risk of CSF dissemination should be closely monitored to ensure early prevention and treatment. The gene discussed is GFAP; the disease is glioblastoma.